WonderBiotics vs PLZ Health: Better for Food Noise?

WonderBiotics vs PLZ Health: Which Better Supports Food Noise and Cravings?

WonderBiotics and PLZ Health both market against "food noise," but through different tools. WonderBiotics pairs a multi-strain probiotic blend with a low-dose metabolic blend, built to sit alongside a GLP-1 or gut-focused routine. PLZ Health's Control My Hunger is a five-ingredient berberine, saffron, 5-HTP, chromium, and Akkermansia stack built as a standalone appetite product. Neither has tested its finished formula on a validated food-noise scale.

What Does "Food Noise" Actually Mean, and Can Either Product Be Tested Against It?

"Food noise" describes persistent, intrusive thoughts about food that go beyond ordinary hunger cues¹. It's a relatively new term, but it now has a validated 5-item scale behind it, the Food Noise Questionnaire (FNQ), developed and tested in a sample of 396 adults with an average BMI of 31². That matters because it means researchers can, in principle, measure whether a product actually changes food noise, instead of relying on vaguer self-reports of "cravings" or "appetite."

Neither WonderBiotics nor PLZ Health has published data using the FNQ, or any comparable validated food-noise instrument, on its finished capsule. (The FNQ validation study itself was funded by WW International, formerly Weight Watchers, and several of its authors are WW employees or shareholders², a funding detail worth knowing alongside the trial disclosures below.) A related but different measure does exist for prescription drugs: in an exploratory subgroup of questionnaire completers from the Novo Nordisk-funded STEP 5 trial, not the full randomized intention-to-treat population, semaglutide showed improvement on a validated Control of Eating Questionnaire over 104 weeks (88 people on semaglutide, 86 on placebo), without correction for multiple comparisons³. However, the CoEQ measures cravings rather than FNQ-defined food noise and does not test either supplement in this comparison.

WonderBiotics vs PLZ Health: Ingredients and Mechanism, Side by Side

WonderBiotics Probiotics for Weight Management is one capsule a day, taken within about 30 minutes of a meal⁴. It combines eight probiotic strains, including Bifidobacterium animalis subsp. lactis B420 and HN019, with polydextrose in a roughly 157 mg probiotic-and-prebiotic blend, plus a separate ~101 mg "metabolic blend" of dihydroberberine and a lemon fruit extract standardized to eriocitrin, marketed as Eriomin®⁴. The pitch is gut-first: quiet cravings and support GI comfort as a companion to weight management or a GLP-1 routine, not as a standalone appetite suppressant.

PLZ Health's Control My Hunger is two capsules a day and skips probiotics for a neurotransmitter-and-metabolism stack: 1,000 mg berberine HCl, 88 mg saffron extract (4:1), 200 mg 5-HTP, 200 mcg chromium picolinate, and 5 billion AFU of pasteurized Akkermansia muciniphila⁵. The company's own "Science" page frames this as supporting GLP-1-adjacent signaling, glucose handling, serotonin-linked mood eating, and gut-barrier integrity together, in one purpose-built product rather than a probiotic add-on⁶.

The overlap is smaller than the marketing language on both sites suggests. Both formulas contain a berberine-family compound, but only PLZ contains pasteurized Akkermansia muciniphila, and only PLZ pairs its stack with 5-HTP, an ingredient with direct central-serotonin activity, and saffron, studied for a possible mood/satiety mechanism rather than demonstrated serotonin activity. WonderBiotics's formula contains neither.

How Strong Is the Evidence Behind Each Ingredient?

Neither company has run a clinical trial on its actual finished capsule. What each has is a set of published trials on individual ingredients, and the quality varies more than either company's marketing copy lets on.

WonderBiotics's headline strain, B420, was tested in a 6-month, 225-person randomized trial funded by the strain's manufacturer, then DuPont, now part of IFF⁷. Its product page cites two numbers from that trial: a 0.94-inch (2.4 cm) waist-circumference reduction and a roughly 320-calorie-a-day drop in self-reported food intake for the B420-only group⁴. Both are real trial findings, but both come from secondary or after-unblinding analyses. The trial's actual pre-registered primary result, DXA-measured body fat change, showed no significant difference across the four study arms overall, and the B420-only group's body-fat change specifically was not statistically significant either⁷. HN019, the formula's other headline strain, has mainly been studied for bowel regularity rather than appetite; its main published trial found no significant difference on its own predefined primary or secondary endpoints, with a modest benefit turning up only in a post-hoc subgroup of people who started with fewer than three bowel movements a week⁸. The cited five-person pharmacokinetic pilot on dihydroberberine was funded by the ingredient's manufacturer, NNB Nutrition, with one author serving as a paid adviser to that company; it found no significant glucose or insulin difference between doses⁹. Eriomin, the eriocitrin extract, has more than one published human trial; the one cited here is a 30-completer crossover study in adults with elevated fasting glucose, funded by Ingredients by Nature, that measured weight and body composition only as secondary outcomes and found no change in either¹⁰. WonderBiotics's entire two-ingredient metabolic blend, dihydroberberine plus the lemon extract combined, totals only about 101 mg, so the label doesn't support a dose or potency comparison against either ingredient's trial dose.

PLZ Health's ingredients carry their own literature, with conflicts of interest of their own. Berberine's weight-related evidence, per a recent review from NIH's National Center for Complementary and Integrative Health, shows decreases in weight and BMI mainly at doses above 1 gram a day taken for 8 or more weeks; PLZ's 1,000 mg dose sits just below that threshold, and the same review lists gastrointestinal symptoms as the primary reported side effect across the underlying studies, which it also flags for high risk of bias¹¹. The trial cited here for saffron extract, an 8-week, 60-woman study, found reduced snacking frequency and modest weight loss at a total daily dose of 176.5 mg¹², about double PLZ's own 88 mg/day, and the specific branded Satiereal extract used in that trial isn't established as equivalent to PLZ's 4:1 extract. 5-HTP has older, preliminary human evidence for reduced food intake and earlier satiety, described by a major cancer center's integrative-medicine reference as suggestive rather than confirmed¹³. Chromium has some preliminary research behind reduced food intake, hunger, and fat cravings, but the NIH Office of Dietary Supplements notes it doesn't help moderate glucose levels in people who don't have diabetes, and describes the weight-related evidence overall as low-quality with effects of "debatable clinical relevance"¹⁴. PLZ's label declares 5 billion AFU of pasteurized Akkermansia a day. The main human trial behind that ingredient used 10 billion cells a day of a studied strain, found improved insulin sensitivity but no statistically significant weight difference versus placebo, and its authors include patent holders and co-founders of the company that commercializes the strain, A-Mansia Biotech¹⁵. AFU and live-cell counts aren't necessarily convertible one-to-one, and PLZ hasn't published which specific Akkermansia strain or material its capsule uses, so this dose can't be measured directly against the trial's.

WonderBiotics's B420, HN019, dihydroberberine, and Eriomin trials were funded by the respective ingredient manufacturers, with company employees or paid advisers among the authors on each. PLZ's berberine, saffron, 5-HTP, chromium, and Akkermansia trials carry their own separate mix of government, company, and patent-holder funding, detailed above. Neither company's funding pattern is cleaner than the other's, and neither has shown that its finished product quiets food noise.

Who Should Be Cautious With Each Product?

PLZ Health's own pages carry specific warnings: they advise against combining Control My Hunger with antidepressants (SSRIs, SNRIs, MAOIs), advise consulting a healthcare professional if taking blood thinners, and advise checking with a doctor before use during pregnancy or breastfeeding^{5, 6}. Medication screening is particularly relevant here because SSRIs and SNRIs are commonly prescribed during perimenopause and menopause for mood, anxiety, or hot flashes. 5-HTP raises serotonin, and combining it with other serotonergic drugs carries a risk of serotonin syndrome; a major cancer center's integrative-medicine database notes at least one published case report (involving the MAOI-class antibiotic linezolid) and advises against combining 5-HTP with SSRIs, SNRIs, or MAOIs without a physician's supervision¹³.

Berberine at PLZ's 1,000 mg dose is also metabolized through liver pathways shared with other medications; NIH's review flags a documented interaction with cyclosporine, recommends checking with a healthcare provider before combining berberine with other prescriptions, and notes it may be unsafe during pregnancy or breastfeeding¹¹. WonderBiotics's metabolic blend contains a related compound, dihydroberberine, but its entire metabolic blend of dihydroberberine plus the lemon extract combined is about 101 mg, versus PLZ's 1,000 mg of berberine alone^{4, 9}; interaction data for dihydroberberine specifically are limited, so reviewing all prescriptions with a pharmacist or prescriber is worth doing either way. The serotonin-syndrome concern specific to PLZ's 5-HTP doesn't apply to WonderBiotics's product, because it doesn't contain that ingredient.

Both products carry the standard structure/function-claim disclaimer that they haven't been evaluated by the FDA and aren't intended to diagnose, treat, cure, or prevent disease; PLZ Health states this directly on its product page⁵. Neither is a substitute for treatment of a diagnosed eating disorder, and neither should be used as a reason to skip or self-adjust a prescribed GLP-1 medication.

Which One Fits Your Situation?

WonderBiotics emphasizes probiotic and GI support: a lower total dose of a berberine-family compound than PLZ's product, no serotonergic ingredient on top of medications many midlife women are already taking, and two headline strains with real, published human trials behind them, even though the specific waist-circumference and calorie-intake numbers on its own site come from secondary, not primary, analyses^{4, 7, 8}. That makes it a fit if you're already on a GLP-1 medication, prefer a gut-health-first approach, or want cravings support alongside general GI comfort. At $55.40 for a one-time purchase, or as low as $41.55 a month on a 6-month subscription, it's also the less expensive of the two products⁴.

PLZ Health's Control My Hunger combines a higher-dose berberine with 5-HTP and saffron, a concentrated, purpose-built stack aimed squarely at appetite and mood-linked eating rather than gut health, and therefore carries different interaction considerations, most notably for anyone taking an SSRI, SNRI, MAOI, or blood thinner. It runs $79.99 one-time or $64.79 a month on subscription⁵. Its five ingredients individually carry independent, non-strain-manufacturer literature, though that literature is smaller in scale and more scattered across compounds and doses, with its own ingredient-specific funding ties noted above.

Neither company can currently show that its finished product quiets food noise on a validated scale. Whichever one you're considering, that's a conversation worth having with your prescriber first, especially in perimenopause and menopause, when SSRI, SNRI, and other prescription use is common.

References

1. Hayashi D, et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients. 2023;15(22):4809. PMC10674813
2. Diktas HE, Cardel MI, Foster GD, et al. Development and validation of the Food Noise Questionnaire. Obesity (Silver Spring). 2025;33(2):289-297. PMID 39828656
3. Wharton S, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023;31(3):703-715. PMID 36655300
4. WonderBiotics. WonderBiotics Probiotics for Weight Management
5. PLZ Health. PLZ Control My Hunger
6. PLZ Health. The Science
7. Stenman LK, et al. Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial. EBioMedicine. 2016;13:190-200. PMID 27810310
8. Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9(3):236-251. PMID 29227175
9. Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients. 2021;14(1):124. PMID 35010998
10. Cesar TB, Ramos FMM, Ribeiro CB. Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial. J Med Food. 2022;25(11):1050-1058. PMID 35796695
11. National Center for Complementary and Integrative Health. Berberine and Weight Loss: What You Need To Know
12. Gout B, Bourges C, Paineau-Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutr Res. 2010;30(5):305-313. PMID 20579522
13. Memorial Sloan Kettering Cancer Center. 5-HTP
14. National Institutes of Health, Office of Dietary Supplements. Chromium – Health Professional Fact Sheet
15. Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096-1103. PMID 31263284